Ethena’s Synthetic Stablecoin Model Challenges USDC’s Market Dominance
Quick Breakdown
- Ethena’s synthetic stablecoin USDe has climbed to the #3 spot, challenging established players like USDC and DAI.
- The launch of USDtb and partnerships with Binance and Jupiter strengthen Ethena’s market credibility.
- Regulatory pressure and volatility risks still shadow its ambition to rival Circle’s USDC dominance.
Ethena’s rapid ascent in the stablecoin market is reshaping discussions around the future of dollar-pegged assets in crypto. With its synthetic dollar, USDe, and a newly launched asset-backed coin, USDtb, the platform is emerging as a serious contender to Circle’s USDC and other leading stablecoins.
— Bybit (@Bybit_Official) October 26, 2025
Dual model targets yield and stability
Unlike traditional stablecoins backed fully by fiat reserves, Ethena’s USDe maintains its dollar peg through trading and hedging strategies in derivatives markets. This synthetic approach has helped USDe climb to the third-largest stablecoin by market capitalization — surpassing DAI and reaching over $12.26 billion. Meanwhile, USDtb, backed by real-world assets and developed with Anchorage Digital, offers a regulated and reserve-backed alternative for risk-averse users.
The dual model reflects Ethena’s broader ambition: to serve both DeFi-native traders seeking yield and institutional clients prioritizing stability and compliance. This strategy has already translated into major milestones, including Binance listing USDe trading pairs and integrating it into its Earn products — a move that boosted the visibility of both USDe and Ethena’s governance token, ENA. Ethena has also partnered with Jupiter, a leading Solana-based DEX, to create JupUSD, designed to replace $750 million worth of USDC in its liquidity pools.
Risks and regulatory uncertainty
Despite its momentum, Ethena’s synthetic model poses clear risks. Because USDe’s peg depends on derivatives markets, extreme volatility could destabilize it as seen during the October 10, 2025, market crash when USDe briefly fell to $0.65 before recovering. The incident reignited concerns about the resilience of algorithmic or synthetic stablecoins under stress.
Regulatory scrutiny adds further complexity. While USDC enjoys established compliance frameworks and institutional trust, synthetic models like Ethena’s face tighter oversight in Europe and uncertain reception in the U.S.
A parallel projection from Citi’s Securities Services Evolution report suggests the broader financial system is also moving toward tokenization. Citi expects that by 2030, one-tenth of global market turnover will be conducted using stablecoins and tokenized securities, reflecting how blockchain-based settlement is steadily merging with traditional post-trade infrastructure.
Take control of your crypto portfolio with MARKETS PRO, DeFi Planet’s suite of analytics tools.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fitness+ business streamlining, $1999 foldable screen and AI strategy take the lead! Apple (AAPL.US) is brewing a new round of strong growth
A more significant catalyst for future performance is the premium product structure upgrade driven by foldable screens, as well as a new wave of iPhone replacement demand prompted by Apple's exclusive AI experience that has been in the works for years.
Qualcomm (QCOM.US) Snapdragon Summit Preview: 2nm Dual-Chip Debuts, AI Diversification Narrative Faces Key Verification
Qualcomm is scheduled to hold its annual Snapdragon Summit in Maui, Hawaii, from September 22 to 24 local time.
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

